Other languages ABL Bio Inc.

Equities

A298380

KR7298380007

End-of-day quote Korea S.E. Other stock markets 03:30:00 07/06/2024 am IST			5-day change	1st Jan Change
24,950 ^KRW	+1.42%		+10.15%	+1.42%

25/03	Biocytogen Pharmaceuticals Co., Ltd. Enters Collaboration with ABL Bio Inc. to Develop New Bispecific Antibody-Drug Conjugates	CI
2023	ABL Bio Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Biocytogen Pharmaceuticals Co., Ltd. Enters Collaboration with ABL Bio Inc. to Develop New Bispecific Antibody-Drug Conjugates	25/03
ABL Bio Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	15/23/15
I-Mab Doses First Patient in Phase 1 Trial of TJ-CD4B to Treat Solid Tumors	22/22/22
ABL Bio Inc. Enters Global Collaboration and License Agreement with SANOFI to Advance ABL301 for the Treatment of Parkinson's Disease	12/22/12

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

+39.41% on our US portfolio vs. 25.67% on the S&P 500 net Total Return

Replicate our performance

fermer